ALERT: We have made the Texas Children’s Health Plan website even easier to use! Click here to learn more.
ALERTA: ¡Ahora el sitio web de Texas Children’s Health Plan es aún más sencillo de usar! Haz clic aquí para más información.
Additional Diagnosis Codes and Place of Service Added for Ravulizumab-cwvz (Ultomiris)
Attention: Hematologists, Gastroenterologists, Rheumatologists
Effective Date: June, 1 2020
Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.
Call to action: Texas Children’s Health Plan (TCHP) would like to inform you that we align with Texas Medicaid Provider Procedure Manual (TMPPM) regarding the guidelines for ravulizumab-cwvz, (Ultomiris), procedure code J1303. The following diagnosis codes have been added as a payable diagnosis for J1303: D588, D593, D594, D595 and D598. A prior authorization is not required for this procedure code.
How this impacts providers: Additional TMPPM guidelines state the following:
- Place of service- office or outpatient hospital
- Members 18 years of age and older